Genomeditech(Shanghai) Co.LTD

EN

EN

CN

Lentivirus

过表达慢病毒干扰慢病毒

Cell Line Development

过表达细胞系构建服务敲低细胞系构建服务敲除细胞系构建服务报告基因细胞株构建服务 Luciferase标记细胞株

Protein Expression

Plasmid DNA Preparation Services

过表达质粒构建干扰质粒构建突变/截短质粒构建荧光素酶报告基因质粒构建

Adeno-associated Virus

过表达AAV 干扰AAV

Cell-based Assay

抗体Binding检测蛋白/抗体药物功能检测 ADCC/P 活性检测 ADC药物CTG杀伤检测 CCK8细胞增值检测克隆形成细胞迁移/侵袭细胞周期/凋亡划痕实验

Antibody Services

Reporter Gene Detection Services

miRNA与靶基因调控研究转录因子调控/promoter活性研究

Plasmid

Stock Plasmid Reporter Plasmid Autophagy Fluorescent Single-Tag Plasmid Empty Vector Cell Tracking Plasmid iPS-Related Plasmids

Cell Lines

Antibody Related Cas9 Cell Tracing Cytokines GPCR Immune Checkpoint Immunology In Vivo Imaging Kinase Metabolism Molecular-Reference-Standards Nuclear Receptors PRR Signalings Pseudovirus TLR TNF Superfamily Transcription Factor Tumor-Associated Antigen(TAA) Others

Molecular Reference Standards

Reporter gene detection-related reagents

GMOne-Step GMOne-Step 2.0 GMBright One-Step GMSteady One-Step Dual Luciferase Reporter Gene Assay Kit D-Luciferin

Lentivirus

Overexpression Lentivirus Reporter Lentivirus In Vivo Imaging Lentivirus iPS-Related Lentivirus Immortalization Lentivirus Autophagy Lentivirus Cre Lentivirus Fluorescent Control Lentivirus

Proteins

ADC Internalization Antibody Related Cytokines GPCR Immune Checkpoint Immunology Kinase Metabolism Others PRR signalings Tumor-Associated Antigen(TAA) TNF Superfamily

Pseudovirus control material

Coronavirus-Like Pseudovirus Influenza-Like Pseudovirus Parainfluenza-Like Pseudovirus Respiratory Syncytial Virus-Like Pseudovirus Rhinovirus-Like Pseudovirus Human Metapneumovirus-Like Pseudovirus Monkeypox-Like Pseudovirus

Reagents related to cell function detection and analysis

GMTiter TM Luminescent Cell Viability Assay Cell Counting kit-8

Adeno-Associated Virus (AAV)

Optogenetics Chemical Genetics Calcium Imaging Cre Recombinase Standard Control Vectors

ADC Antibodies

ADC Biosimilar Antibodies ADC Isotype Antibodies ADC Related Antibodies Anti-payload Antibodies

Pseudovirus

SARS-CoV-2 pseudovirus Rabies Pseudovirus SARS Pseudovirus Influenza pseudovirus MERS pseudovirus HIV-1 Pseudovirus

Genoagent (Brand name of reagents)

lentiviral-packaging-tool Transfection Reagent Mycoplasma Removal Reagent Antibiotic Gene Knockout Kit Polybrene Switch-On Reagent Staphylococcal Enterotoxin E

News

Insights Resources Activity

News

Insights

Resources

Activity

Current position：News > News

News

Leave Your Comment & Get 20% Off

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

Share Your Cell Line Experience. Get Rewarded.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

Will B7-H3 Become the Next Major ADC Target?

The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

Could GDF15 Become the Next Super Target After PD-1 and GLP-1?

A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.

ADCC, ADCP, and CDC: Antibody Structure and Class Considerations

Antibodies have evolved into versatile therapeutic platforms, capable of not only targeting disease cells but also activating the immune system through ADCC, ADCP, and CDC. Advances in Fc engineering—such as glycoengineering, targeted mutations, and FcRn optimization—are now enhancing antibody potency, selectivity, and half-life, unlocking new opportunities in oncology, autoimmune disorders, and infectious diseases.

BCMA Drives Accelerated Expansion into the Autoimmune Therapeutics Field

BCMA, a well-established target in blood cancers, is now expanding its impact into autoimmune diseases. Leveraging its highly specific expression and favorable safety profile, BCMA is at the forefront of innovative therapies, including CAR-T cells, bispecific and trispecific antibodies, and antibody-drug conjugates.

Recent collaborations and rapid clinical advancements highlight BCMA as a key focus for next-generation immune-targeted treatments. Learn how this promising target is reshaping the future of immunotherapy and opening new possibilities for patients worldwide.

First 1 2 3 4 5 Next Last

Total 7 Page

Jump

Current position：News > News

classify

News

Leave Your Comment & Get 20% Off

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

Share Your Cell Line Experience. Get Rewarded.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

Will B7-H3 Become the Next Major ADC Target?

The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

Could GDF15 Become the Next Super Target After PD-1 and GLP-1?

A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.

ADCC, ADCP, and CDC: Antibody Structure and Class Considerations

Antibodies have evolved into versatile therapeutic platforms, capable of not only targeting disease cells but also activating the immune system through ADCC, ADCP, and CDC. Advances in Fc engineering—such as glycoengineering, targeted mutations, and FcRn optimization—are now enhancing antibody potency, selectivity, and half-life, unlocking new opportunities in oncology, autoimmune disorders, and infectious diseases.

BCMA Drives Accelerated Expansion into the Autoimmune Therapeutics Field

BCMA, a well-established target in blood cancers, is now expanding its impact into autoimmune diseases. Leveraging its highly specific expression and favorable safety profile, BCMA is at the forefront of innovative therapies, including CAR-T cells, bispecific and trispecific antibodies, and antibody-drug conjugates.

Recent collaborations and rapid clinical advancements highlight BCMA as a key focus for next-generation immune-targeted treatments. Learn how this promising target is reshaping the future of immunotherapy and opening new possibilities for patients worldwide.

MORE

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation